Pressmeddelande -

AddBIO: Clinical results – implants with bisphosphonate show improved stability

AddBIO AB, a subsidiary of Accelerator Nordic AB, has developed Zolidd®, a proprietary bioactive nanolayer for orthopedic and dental implants that releases bisphosphonate, a bone strengthening drug. A randomized clinical trial, conducted at Linköping University Hospital, Sweden, shows that dental implants with a bisphosphonate nanolayer have improved stability.

Millions of people worldwide have dental implants, i.e. screws inserted to support artificial teeth. The first time after surgery, the implant is often not stable enough to enable chewing. It may take several months for the bone around the implant to heal and become strong enough for the patient to regain normal chewing function.

“The study shows that local bisphosphonate improves implant stability, meaning that the time until normal chewing function could be shortened, thus reducing the suffering for the patient”, says Professor Per Aspenberg, Linköping University Hospital, co-founder of AddBIO.

Zolidd is the first application from a platform technology designed for local release of drugs from medical implants, developed by Professors Per Aspenberg and Penti Tengvall, Linköping University. A nanometer-thin protein layer is attached to the metal surface and a bisphosphonate is attached to the protein. When the bisphosphonate is released, a local effect is obtained, which improves implant stability. In the present study, a Zolidd prototype was used to release bisphosphonate in this way.

Sixteen patients each received two implants, one with bisphosphonate and one without. After six months, the bisphosphonate treated implant showed improved stability in 15 out of 16 patients. On x-rays, the treated implants showed positive effects already after two months. No complications occurred.

”This is an important study. With these results, we are now ready to take the next step in commercializing Zolidd”, says Dr. Trine Vikinge, CEO AddBIO.

The study was conducted by Jahan Abtahi, Department of Experimental and Clinical Medicine, Faculty of Health Science, Linköping University, supported by Per Aspenberg. It has now been published online in BONE (http://dx.doi.org/10.1016/j.bone.2012.02.001).

 

For additional information, contact Andreas Bunge, CEO Accelerator Nordic AB, +46 70 824 25 25.

Ämnen

  • Ekonomi, finans

Kategorier

  • dental implants
  • orthopedic implants
  • bisphosphonate
  • per aspenberg
  • addbio
  • accelerator

Regioner

  • Skåne

Accelerator Nordic AB is a group of Life Science companies focused on Imaging Software and Medical Nanotechnology. Accelerator’s subsidiaries have exposure towards large growth markets such as oncology, orthopedics, and diagnostics. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm, Sweden. For more information please visit, www.acceleratorab.se.

Kontakter

Thomas Gür

Presskontakt VD +46 8 663 57 06

Relaterad media

AddBIO: Clinical results – implants with bisphosphonate show improved stability
  • AddBIO: Clinical results – implants with bisphosphonate show improved stability
  • Licens: Medieanvändning
    Innehållet får laddas ner, användas och delas i olika mediekanaler av t.ex. journalister, bloggare, krönikörer, opinionsbildare etc., i syftet att förmedla, redogöra för och kommentera ert pressmeddelande, inlägg eller information, så länge innehållet används oförändrat och i dess helhet. Upphovsmannen ska anges i den omfattning och på det sätt god sed kräver (vilket bl.a. innebär att fotografer till bilder nästan alltid måste anges).
  • Filformat: .pdf
Ladda ner

Relaterat innehåll

AddBIO: Kliniska resultat - implantat med bisfosfonat sitter bättre fast i ben

Accelerators dotterbolag AddBIO har utvecklat Zolidd®, ett patenterat nanolager som frisätter bisfosfonat, ett benstärkande läkemedel, för ortopediska och dentala implantat. En klinisk forskningsstudie som genomförts vid universitetssjukhuset i Linköping visar att dentala implantat som behandlats med bisfosfonat sitter bättre fast i benet.

AddBIO appoints new board members

AddBIO AB, subsidiary of Accelerator Nordic AB, has appointed Gunilla Lundmark, Dr. Andy Carter and Maria Fors to the company’s board of directors.

Almi Invest investerar i AddBIO

Accelerators dotterbolag AddBIO tar in maximalt 9,4 miljoner kronor i en nyemission i vilken Almi Invest investerar 3 miljoner kronor och Accelerator 4,2 miljoner kronor. AddBIO får samtidigt ytterligare två nya ägare som tillsammans med andra befintliga ägare investerar resterande 2,2 miljoner kronor.

AddBIO recruits Ulf Sewerin as CEO

AddBIO AB, subsidiary of Accelerator Nordic AB, has recruited Ulf Sewerin as CEO.

Bisphosphonates improve implant stability

Artikel i British Dental Journal (BDJ) om de positiva kliniska resultat som nyligen publicerades kring AddBIOs produkt Zolidd.

Uppmärksammad studie: AddBIO visar positiva resultat med tandimplantat i klinik

Den 16 februari hade vi nöjet att berätta att en klinisk studie som utförts vid universitetssjukhuset i Linköping nu publicerats med mycket positiva resultat som visar att implantat som behandlats med bisfosfonat enligt AddBIOs teknik sitter bättre fast i benet. Studien har uppmärksammats av flera media, bland annat BiotechSweden, NyTeknik och Dental24.